Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 19 de 19
Filter
1.
BMJ Case Rep ; 17(2)2024 Feb 20.
Article in English | MEDLINE | ID: mdl-38378593

ABSTRACT

Monkeypox virus belongs to the genus Orthopoxvirus There was a worldwide mpox outbreak in 2022, with many cases reported in Europe in gay, bisexual and other men who have sex with men. Here, we report a case of mpox diagnosed in a heterosexual woman in her twenties without any known history of exposure. This is a very rare event. Despite lesions remaining for more than 1 month, she recovered fully with no sequelae. We highlight the diagnosis of mpox in a heterosexual woman without a known or suspected history of exposure or any risk factor for acquiring the infection.


Subject(s)
Mpox (monkeypox) , Sexual and Gender Minorities , Female , Male , Humans , Homosexuality, Male , Mpox (monkeypox)/diagnosis , Mpox (monkeypox)/epidemiology , Disease Outbreaks , Bisexuality
2.
BMC Infect Dis ; 22(1): 310, 2022 Mar 29.
Article in English | MEDLINE | ID: mdl-35351021

ABSTRACT

BACKGROUND: Actinomycosis is an uncommon endogenous bacterial infection caused by Actinomyces species, characterized by the development of abscesses, tissue fibrosis, and fistulisation. It remains a diagnostic challenge, due to its similarities with diverse aetiologies' presentation, such as neoplasms, tuberculosis, or fungal infections. Actinomyces bovis is a microorganism rarely reported as a cause of human disease. Cutaneous involvement is sporadic. In this case, Actinomyces bovis was responsible for disseminated cutaneous disease in an immunosuppressed patient. CASE PRESENTATION: We report the case of a 69-year-old female with multiple skin masses, under immunosuppressive therapy due to ulcerative colitis. Imaging exams were compatible with multiple cutaneous abscesses in the cervicofacial region and limbs. Actinomyces bovis was isolated in culture after abscess drainage. Antimicrobial therapy with parenteral penicillin G and oral amoxicillin was administered for 6 months, with complete resolution of cutaneous lesions and no relapse of the infection. CONCLUSIONS: Considering actinomycosis as a possible diagnosis in the presence of subacute/chronic recurrent mass-like cutaneous lesions, especially in the setting of immunosuppression, may reduce the burden associated with delayed diagnosis and incorrect treatment and provide better outcomes and improvement of patient's quality of life.


Subject(s)
Actinomycosis , Quality of Life , Actinomyces , Actinomycosis/diagnosis , Actinomycosis/drug therapy , Actinomycosis/microbiology , Aged , Female , Humans , Immunocompromised Host
3.
J Med Virol ; 93(11): 6388-6392, 2021 11.
Article in English | MEDLINE | ID: mdl-34260070

ABSTRACT

Amino acid insertions have been rarely found in the integrase (IN) coding region of Human immunodeficiency virus 1 (HIV-1), and have been considered as natural polymorphisms. It is still unclear the potential impact of these insertion mutations on the viral replication capacity and/or susceptibility to integrase strand transfer inhibitors (INSTIs). The objective of this study was to describe a previously unreported amino acid insertion in the IN coding region of HIV-1 isolates obtained from antiretroviral treatment-naïve infected individuals. Nucleotide sequences of HIV-1 isolates obtained from two infected individuals were analyzed for genotypic resistance to antiretroviral drugs. Phylogenetic inference was carried out for HIV-1 genetic variant identification. An unreported insertion of a threonine (T) and an asparagine (N) between codon 255 and 256 (S255N_TN) was identified in the IN C-terminal domain of HIV-1 subtype G isolates. No resistance-associated mutations to INSTIs were detected in the inserted sequences. Both individuals maintained undetectable HIV-1 RNA viral load, 24 months after undergoing antiretroviral treatment with an INSTI containing regimen. The results demonstrated the possibility of transmission of this insertion mutation and suggested that the codon 255 insert by itself may not affect susceptibility to INSTIs.


Subject(s)
Amino Acids/genetics , Frameshift Mutation , HIV Integrase/genetics , HIV-1/genetics , Open Reading Frames/genetics , Anti-Retroviral Agents/therapeutic use , Drug Resistance, Viral/genetics , Female , Genotype , HIV Infections/drug therapy , HIV Infections/virology , HIV Integrase Inhibitors/pharmacology , HIV-1/classification , Humans , Male , Mutation , Phylogeny , Sequence Analysis, DNA
4.
J Infect Dev Ctries ; 15(3): 320-325, 2021 03 31.
Article in English | MEDLINE | ID: mdl-33839704

ABSTRACT

INTRODUCTION: The COVID-19 epidemic has been causing serious physical, but also psychological effects in society. This systematic review sought to identify studies that describe COVID-19 related anxiety, and to understand the impact of anxiety assessment in defining strategies to be implemented in future studies. METHODOLOGY: This systematic review included cross-sectional studies with no publication year limit. It was performed a systematic search through three databases, namely, PubMed, Science Direct and Web of Science using the descriptors "COVID-19" and "anxiety". PRISMA criteria reporting of systematic reviews and meta-analyses were applied. Eligible articles were selected in accordance with inclusion and exclusion criteria. The inclusion criteria were: research articles related with anxiety measurement during the COVID-19 outbreak; interventions to reduce anxiety; and published in English. RESULTS: From 44 references, just four scientific articles were accepted for inclusion within this review. These studies were analyzed regarding their sample, methodology, instruments used, and its results. CONCLUSIONS: This systematic review was based on published data at the onset of the pandemic, and it could serve as a basis for the development of implementations plans to improve anxiety disorders. The importance of this theme, the implications and potential directions for future investigations will be discussed.


Subject(s)
Anxiety/epidemiology , COVID-19/psychology , Cross-Sectional Studies , Global Health , Humans
5.
IDCases ; 23: e01017, 2021.
Article in English | MEDLINE | ID: mdl-33335835

ABSTRACT

Mumps is an infectious disease caused by a paramyxovirus. It can involve several organs in the acute stage of the infection, including central nervous system. (Rubin et al., 2015) [1] Neurological complications in the post-infectious period are also described, one of which is acute disseminated encephalomyelitis (ADEM). (Jonhson et al., 2004) [2] We present the case of an healthy young man previously vaccinated, who contracted ADEM after mumps.

6.
IDCases ; 22: e00983, 2020.
Article in English | MEDLINE | ID: mdl-33194546

ABSTRACT

Central nervous system infection caused by Herpes simplex virus 1 remains a significant cause of morbidity and mortality in transplant patients. Additionally, the clinical implications of the recently discovered Human herpesvirus 6A are still under investigation. Hereby, we report a clinical case of an immunosuppressed patient following kidney transplantation and with chromosomally integrated human herpesvirus-6A (CIHHV-6A) that developed rhombencephalitis due to herpes virus simplex 1. This case highlights the importance of investigating the CIHHV-6 status in the differential diagnosis whenever a human herpesvirus is detected in the cerebrospinal fluid.

8.
J Antimicrob Chemother ; 72(10): 2869-2878, 2017 10 01.
Article in English | MEDLINE | ID: mdl-29091198

ABSTRACT

Background: CD4 cell recovery following first-line combination ART (cART) is poorer in HIV-2+ than in HIV-1+ patients. Only large comparisons may allow adjustments for demographic and pretreatment plasma viral load (pVL). Methods: ART-naive HIV+ adults from two European multicohort collaborations, COHERE (HIV-1 alone) and ACHIeV2e (HIV-2 alone), were included, if they started first-line cART (without NNRTIs or fusion inhibitors) between 1997 and 2011. Patients without at least one CD4 cell count before start of cART, without a pretreatment pVL and with missing a priori-defined covariables were excluded. Evolution of CD4 cell count was studied using adjusted linear mixed models. Results: We included 185 HIV-2+ and 30321 HIV-1+ patients with median age of 46 years (IQR 36-52) and 37 years (IQR 31-44), respectively. Median observed pretreatment CD4 cell counts/mm3 were 203 (95% CI 100-290) in HIV-2+ patients and 223 (95% CI 100-353) in HIV-1+ patients. Mean observed CD4 cell count changes from start of cART to 12 months were +105 (95% CI 77-134) in HIV-2+ patients and +202 (95% CI 199-205) in HIV-1+ patients, an observed difference of 97 cells/mm3 in 1 year. In adjusted analysis, the mean CD4 cell increase was overall 25 CD4 cells/mm3/year lower (95% CI 5-44; P = 0.0127) in HIV-2+ patients compared with HIV-1+ patients. Conclusions: A poorer CD4 cell increase during first-line cART was observed in HIV-2+ patients, even after adjusting for pretreatment pVL and other potential confounders. Our results underline the need to identify more potent therapeutic regimens or strategies against HIV-2.


Subject(s)
Anti-HIV Agents/therapeutic use , CD4 Lymphocyte Count , HIV Infections/immunology , HIV Infections/virology , HIV-1/drug effects , HIV-2/drug effects , Adult , Anti-HIV Agents/administration & dosage , Anti-HIV Agents/adverse effects , CD4-Positive T-Lymphocytes/immunology , CD4-Positive T-Lymphocytes/virology , Cohort Studies , Europe , Female , HIV Infections/blood , HIV Infections/drug therapy , Humans , Internationality , Male , Middle Aged , RNA, Viral/blood , Viral Load
9.
J Infect Dev Ctries ; 6(3): 290-4, 2012 Mar 12.
Article in English | MEDLINE | ID: mdl-22421613

ABSTRACT

We describe the case of a 14-year-old Caucasian male, a resident in the Democratic Republic of the Congo, who was observed in Portugal with severe Plasmodium falciparum malaria with high-level parasitemia and severe thrombocytopenia. The course was complicated by bilateral sixth cranial nerve palsy during acute malaria, followed by the appearance of delayed cerebellar ataxia during the recovery phase. This occurred after successful treatment with quinine plus doxycycline over seven days. Different levels of thrombocytopenia and C-reactive protein were observed during both neurologic events in the presence of HRP-2 positive tests for Plasmodium falciparum antigen. The patient recovered completely after three months.


Subject(s)
Abducens Nerve Diseases/complications , Antimalarials/therapeutic use , Cerebellar Ataxia/complications , Malaria, Falciparum/complications , Abducens Nerve Diseases/drug therapy , Adolescent , Cerebellar Ataxia/drug therapy , Doxycycline/therapeutic use , Humans , Malaria, Falciparum/drug therapy , Malaria, Falciparum/parasitology , Male , Parasitemia/complications , Parasitemia/drug therapy , Plasmodium falciparum , Quinine/therapeutic use
10.
J Med Virol ; 84(4): 551-4, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22337292

ABSTRACT

Etravirine (ETR) is a non-nucleoside analogue reverse transcriptase inhibitor (NNRTI) with a high genetic barrier to the development of resistance and with potential activity against Human immunodeficiency virus type 1 (HIV-1) strains resistant to first-generation NNRTIs. The objective of this study was to investigate the prevalence of ETR resistance associated mutations (RAMs) in HIV-1 strains isolated from infected individuals failing efavirenz (EFV), as well as to evaluate possible differences in the distribution of ETR RAMs between subtype B and non-B genetic variants. Nucleotide sequences of the protease and partial reverse transcriptase (RT) coding regions of the pol gene of 55 HIV-1 strains isolated from infected individuals failing EFV on regular follow-up at a reference center in Portugal, were retrospectively analyzed. The most prevalent ETR RAMs observed were L100I, V90I, and K101E, with a prevalence of 16.4% (n = 9), 9.1% (n = 5), and 5.5% (n = 3), respectively. Overall, 47.3% (n = 26) of the nucleotide sequences had at least one ETR RAM: 38.2% (n = 21) had one ETR RAM, 7.3% (n = 4) had two ETR RAMs and 1.8% (n = 1) had three ETR RAMs. No statistically significant differences were found in the distribution of ETR RAMs between subtype B and non-B genetic variants. The results demonstrate that ETR rescue therapy is a viable option in treatment-experienced individuals failing EFV and suggests that ETR may be equally useful in HIV-1 infections caused by different genetic variants.


Subject(s)
Anti-HIV Agents/pharmacology , Drug Resistance, Viral , HIV Infections/virology , HIV-1/drug effects , HIV-1/genetics , Pyridazines/pharmacology , Alkynes , Anti-HIV Agents/therapeutic use , Benzoxazines/therapeutic use , Cyclopropanes , Genotype , HIV Infections/drug therapy , HIV Protease/genetics , HIV Reverse Transcriptase/genetics , HIV-1/classification , HIV-1/isolation & purification , Humans , Mutant Proteins/genetics , Mutation, Missense , Nitriles , Portugal , Prevalence , Pyrimidines , Retrospective Studies , Treatment Failure
11.
J Infect Dev Ctries ; 6(2): 201-3, 2012 Feb 13.
Article in English | MEDLINE | ID: mdl-22337852

ABSTRACT

Hepatitis E infection is usually a self-limiting disease. In industrialized countries, sporadic cases of acute hepatitis E virus (HEV) infections have been described; their number seems to be increasing in European countries. We report the first human case of autochthonous acute hepatitis E confirmed in Portugal. Patients with acute non-A-C hepatitis should be tested for HEV in Portugal and hepatitis E infection should be considered in the differential diagnosis of unexplained hepatitis cases.


Subject(s)
Hepatitis E virus/isolation & purification , Hepatitis E/diagnosis , Aged , Hepatitis E/pathology , Humans , Male , Portugal
12.
J Infect Chemother ; 18(1): 105-8, 2012 Feb.
Article in English | MEDLINE | ID: mdl-21879306

ABSTRACT

Mediterranean spotted fever (MSF) is a disease caused by Rickettsia conorii and transmitted by the brown dog tick Rhipicephalus sanguineus. It is widely distributed through southern Europe, Africa, and the Middle East. It is an emerging or a reemerging disease in some regions. Countries of the Mediterranean basin, such as Portugal, have noticed an increased incidence of MSF over the past 10 years. It was believed that MSF was a benign disease associated with a mortality rate of 1-3% before the antimicrobial drug era. It was called benign summer typhus. Severe forms were described in 1981, and the mortality rate reached 32% in Portugal in 1997. However, neurological manifestations associated with brain lesions are a rare event. We describe the case of a man with fever, maculopapular rash, a black spot, and hemisensory loss including the face on the left side of the body with brain lesions in the imaging studies.


Subject(s)
Boutonneuse Fever/pathology , Encephalitis/microbiology , Rickettsia conorii , Anti-Bacterial Agents/therapeutic use , Boutonneuse Fever/drug therapy , Boutonneuse Fever/microbiology , Brain/pathology , Doxycycline/therapeutic use , Encephalitis/drug therapy , Humans , Insect Bites and Stings , Magnetic Resonance Imaging , Male , Middle Aged , Thigh/pathology
13.
J Gen Virol ; 93(Pt 4): 692-697, 2012 Apr.
Article in English | MEDLINE | ID: mdl-22158878

ABSTRACT

JC virus (JCV) is ubiquitous in the human population. Primary infection normally occurs during childhood and is followed by a lifelong persistent infection. The main mode of transmission remains unknown. Several authors have hypothesized that JCV transmission occurs through the respiratory route, and that respiratory secretions could represent a possible source of viral particles. The present study intended to evaluate oropharyngeal fluids from patients infected with JCV, in order to ascertain if respiratory secretions could indeed constitute a source of exposure to this polyomavirus. Oropharyngeal washing samples from 25 patients co-infected with JCV and human immunodeficiency virus type 1 were evaluated for the presence of JCV DNA. Regardless of the titre of antibodies or the presence of viral urinary excretion, JCV genome was not detected in oropharyngeal samples collected from any of the patients infected with JCV included in this study, which may suggest that oropharyngeal fluids are an unlikely source for JCV infection.


Subject(s)
DNA, Viral/analysis , JC Virus/isolation & purification , Mouth/virology , Pharynx/virology , Polyomavirus Infections/virology , Tumor Virus Infections/virology , Adult , Body Fluids/chemistry , Body Fluids/virology , Female , Humans , Male , Middle Aged , Mouth/chemistry , Pharynx/chemistry , Respiratory System/virology
14.
J Infect Dev Ctries ; 5(9): 658-63, 2011 Sep 14.
Article in English | MEDLINE | ID: mdl-21918307

ABSTRACT

INTRODUCTION: In June 2009, the World Health Organization declared an influenza pandemic associated with the pandemic (H1N1) 2009 strain. It was summer in the northern hemisphere, and therefore travelling and vacation time, which also provided an increased opportunity for the dissemination of respiratory diseases. METHODOLOGY: We reviewed the paper case report forms from all the patients with influenza-like illnesses with nasopharyngeal samples submitted for laboratory diagnosis of pandemic (H1N1) 2009 infection during the first wave of pandemic influenza that occurred between June and August 2009, in the central region of Portugal. RESULTS: From all the patients with influenza-like illnesses, one third was found positive for pandemic (H1N1) 2009. Individuals under the age of 29 (75%) were the most affected. Most of the patients (91%) presented with fever. A group of symptoms were positively correlated with the probability of pandemic (H1N1) 2009 infection: cough, epistaxis, lack of dyspnea or vomiting, fever, headache and myalgia. CONCLUSIONS: During the first wave of the pandemic influenza, young individuals were the most affected, and in the ambulatory setting, presentation was of a mild febrile illness without complications.


Subject(s)
Influenza A Virus, H1N1 Subtype/isolation & purification , Influenza, Human/diagnosis , Influenza, Human/epidemiology , Adolescent , Adult , Aged , Aged, 80 and over , Female , Fever , Humans , Influenza Vaccines/administration & dosage , Influenza, Human/prevention & control , Influenza, Human/virology , Logistic Models , Male , Middle Aged , Pandemics , Portugal/epidemiology , Risk Factors , Young Adult
15.
J Clin Microbiol ; 49(10): 3491-7, 2011 Oct.
Article in English | MEDLINE | ID: mdl-21813718

ABSTRACT

Accurate HIV-2 plasma viral load quantification is crucial for adequate HIV-2 patient management and for the proper conduct of clinical trials and international cohort collaborations. This study compared the homogeneity of HIV-2 RNA quantification when using HIV-2 assays from ACHI(E)V(2E) study sites and either in-house PCR calibration standards or common viral load standards supplied to all collaborators. Each of the 12 participating laboratories quantified blinded HIV-2 samples, using its own HIV-2 viral load assay and standard as well as centrally validated and distributed common HIV-2 group A and B standards (http://www.hiv.lanl.gov/content/sequence/HelpDocs/subtypes-more.html). Aliquots of HIV-2 group A and B strains, each at 2 theoretical concentrations (2.7 and 3.7 log(10) copies/ml), were tested. Intralaboratory, interlaboratory, and overall variances of quantification results obtained with both standards were compared using F tests. For HIV-2 group A quantifications, overall and interlaboratory and/or intralaboratory variances were significantly lower when using the common standard than when using in-house standards at the concentration levels of 2.7 log(10) copies/ml and 3.7 log(10) copies/ml, respectively. For HIV-2 group B, a high heterogeneity was observed and the variances did not differ according to the type of standard used. In this international collaboration, the use of a common standard improved the homogeneity of HIV-2 group A RNA quantification only. The diversity of HIV-2 group B, particularly in PCR primer-binding regions, may explain the heterogeneity in quantification of this strain. Development of a validated HIV-2 viral load assay that accurately quantifies distinct circulating strains is needed.


Subject(s)
HIV Infections/virology , HIV-2/isolation & purification , Viral Load/methods , Humans , International Cooperation , Observer Variation , Plasma/virology , Quality Control , Reference Standards , Reproducibility of Results , Viral Load/standards
17.
J Med Virol ; 82(3): 494-504, 2010 Mar.
Article in English | MEDLINE | ID: mdl-20087944

ABSTRACT

JC virus (JCV) is ubiquitous in the human population, infecting children asymptomatically. After primary infection, JCV persists in the host throughout life and is often excreted in the urine. Two hundred thirty-four urine samples and 78 serum samples, collected from 171 healthy individuals and 63 patients infected with HIV, were used to characterize JCV infection in a Portuguese population. Using PCR, JCV DNA was detected in 38% of the urine samples. A significant difference in the excretion rate was observed between patients infected with HIV (51%) and healthy individuals (33%). The frequency of JCV viruria increased with age in healthy individuals, but not in patients infected with HIV. JCV urinary load was determined by real-time quantitative PCR and was independent of gender, age, HIV infection, and CD4+ cell count. Overall, the JCV genotype detected most commonly was 1B, followed by genotypes 2B and 4. The detection and quantitation of JCV-specific antibodies were performed in serum samples by an established enzyme immunoassay (EIA). Antibodies to JCV were observed in 91% of the patients tested, irrespective of HIV infection. A positive correlation between JCV urinary load and antibody titers was demonstrated. The present study provides the first characterization of seroprevalence and urinary excretion of JCV in a Portuguese population and revealed similar results to those observed in other European countries. A comparison between healthy individuals and patients infected with HIV, despite identical values of seroprevalence, showed some differences in the pattern of urinary excretion. J. Med. Virol. 82:494-504, 2010. (c) 2010 Wiley-Liss, Inc.


Subject(s)
JC Virus/isolation & purification , Polyomavirus Infections/epidemiology , Polyomavirus Infections/virology , Tumor Virus Infections/epidemiology , Tumor Virus Infections/virology , Adolescent , Adult , Aged , Antibodies, Viral/blood , Child , Child, Preschool , DNA, Viral/genetics , Female , Genotype , HIV Infections/complications , Humans , Immunoenzyme Techniques , JC Virus/classification , JC Virus/genetics , Male , Middle Aged , Polymerase Chain Reaction , Portugal/epidemiology , Prevalence , Seroepidemiologic Studies , Serum/virology , Urine/virology , Young Adult
18.
J Clin Virol ; 46(2): 169-72, 2009 Oct.
Article in English | MEDLINE | ID: mdl-19625212

ABSTRACT

BACKGROUND: Amino acids insertions in the protease (PR) coding region have been reported in protease inhibitors (PIs) treatment-naïve and experienced HIV-1 infected individuals ranging from 0.1% to 4.55% and have been rarely found in non-B HIV-1 subtype strains. OBJECTIVES: To investigate the presence of amino acid insertions in the PR coding region in sequences from treatment-naïve HIV-1 infected individuals in the Central Region of Portugal. STUDY DESIGN: Sequences of the pol gene from 260 treatment-naïve HIV-1 infected individuals between 2000 and 2008 were analyzed and phylogenetic analysis was performed. RESULTS: A threonine insertion (E35E_T) was detected in 2.69% (n=7) of the sequences analyzed and all the sequences that possessed this insertion were identified as subtype C. All the seven inserted sequences clustered in the same lineage of the phylogenetic tree. Heterosexual and intravenous drug use were found to be the routes of infection. No major mutations in the PR coding region associated with resistance to PIs were detected. CONCLUSIONS: It was found the highest prevalence of PR codon 35 insertion among treatment-naïve HIV-1 infected individuals ever reported in the western countries. Epidemiological data and Phylogenetic analysis indicated the possibility of transmission of this insertion. The results suggested that these inserted strains have normal susceptibility to PIs containing regimens. This study demonstrated the spreading epidemic of PR codon 35 inserted strains from subtype C in the Central Region of Portugal, during the past eight years.


Subject(s)
HIV Infections/virology , HIV Protease/genetics , HIV-1/enzymology , Mutagenesis, Insertional/genetics , Female , HIV Infections/epidemiology , HIV-1/genetics , Humans , Male , Phylogeny , Portugal/epidemiology
19.
J Pediatr Gastroenterol Nutr ; 39(5): 560-3, 2004 Nov.
Article in English | MEDLINE | ID: mdl-15572901

ABSTRACT

OBJECTIVES: To review clinical, laboratory, endoscopic and histologic features, treatment and outcome of immunocompetent children with Herpes simplex virus esophagitis. METHODS: Retrospective analysis of the medical records of six children (five males) referred to our unit between 1997-2001. RESULTS: The median age at presentation was 4 years. Fever was present in all, odynophagia/dysphagia in five, retrosternal pain in four, vomiting in three, drooling in two and irritability and drowsiness in one. The median time between the onset of symptoms and the diagnosis was 6.5 days. Endoscopy, performed in all, showed friable mucosa and erosive-ulcerative involvement, with histology showing inflammation and ulcerated esophagitis. Tissue viral culture was performed in five patients and was positive in three, and polymerase chain reaction was positive in two of four tested. Serology was consistent with primary Herpes simplex virus infection in all. All received nasogastric feeding and acyclovir. The outcome was very good. CONCLUSIONS: This is an uncommon and under-recognized condition in the immunocompetent child. The most common symptoms are sometimes not diagnostic, particularly in very young children. The presence of unusual clinical signs may lead to a difficult and delayed diagnosis. Treatment with acyclovir may have hastened the resolution of symptoms, but a controlled clinical study was not performed.


Subject(s)
Acyclovir/therapeutic use , Antiviral Agents/therapeutic use , Esophagitis/virology , Immunocompromised Host/immunology , Simplexvirus/isolation & purification , Biopsy , Child , Child, Preschool , Esophagitis/diagnosis , Esophagitis/drug therapy , Esophagoscopy , Female , Humans , Infant , Male , Retrospective Studies , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...